Patterson Companies, Inc. (Nasdaq: PDCO), announced that it has, through subsidiaries, successfully completed the previously announced acquisition of substantially all of the assets of Relief Services for Veterinary Practitioners and Animal Care Technologies (“RSVP” and “ACT,” respectively), Texas-based companies that provide innovative solutions to veterinary practices through data extraction and conversion, staffing and video-based training services.
The acquired businesses are expected to be integrated into Patterson Veterinary’s existing operations and teams.
“We are pleased to add RSVP and ACT’s capabilities and team expertise to our suite of offerings and our operating team,” said George Henriques, president of Patterson Companion Animal. “We welcome our new colleagues to Patterson and look forward to continued success together.”
About Patterson Companies Inc.
Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain are equaled only by our dedicated, knowledgeable people who deliver unrivaled expertise and unmatched customer service and support.
Learn more: pattersoncompanies.com
| Last Trade: | US$26.02 |
| Daily Change: | 0.55 2.16 |
| Daily Volume: | 503,630 |
| Market Cap: | US$2.330B |
February 28, 2024 November 29, 2023 November 20, 2023 August 30, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
